In the present study, the expression of ECHDC3 could divide int-risk AML and FLT3+NPM1+AML into two subgroups with distinct survival rates, which might improve the prediction of the survival and guide post-remission treatment in int-risk AML. Here, FLT3 is linked to acute myeloid leukemia.